PL90039B1 - - Google Patents
Download PDFInfo
- Publication number
- PL90039B1 PL90039B1 PL1970173765A PL17376570A PL90039B1 PL 90039 B1 PL90039 B1 PL 90039B1 PL 1970173765 A PL1970173765 A PL 1970173765A PL 17376570 A PL17376570 A PL 17376570A PL 90039 B1 PL90039 B1 PL 90039B1
- Authority
- PL
- Poland
- Prior art keywords
- formula
- aryl
- wzdr
- halogen
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- -1 nitrilalkyl Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000002825 nitriles Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
- 150000003944 halohydrins Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- MFEDKMBNKNOUPA-UHFFFAOYSA-N (2-bromo-4,7-dimethyl-3-oxo-7-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(C)C(=O)C(Br)C1C2(CS(O)(=O)=O)C MFEDKMBNKNOUPA-UHFFFAOYSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- ISRQTIXRVQQREA-UHFFFAOYSA-N 1-amino-1-(2-bromophenoxy)-3-(1-methylcycloheptyl)propan-2-ol Chemical compound BrC1=C(OC(C(CC2(CCCCCC2)C)O)N)C=CC=C1 ISRQTIXRVQQREA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FJRYUYOWGGVHLU-UHFFFAOYSA-N C(#C)C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 Chemical compound C(#C)C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 FJRYUYOWGGVHLU-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04H—BUILDINGS OR LIKE STRUCTURES FOR PARTICULAR PURPOSES; SWIMMING OR SPLASH BATHS OR POOLS; MASTS; FENCING; TENTS OR CANOPIES, IN GENERAL
- E04H13/00—Monuments; Tombs; Burial vaults; Columbaria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Architecture (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Structural Engineering (AREA)
- Civil Engineering (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Przedmiotem wynalazku jest sposób wytwarzania nowych racemicznych lub optycznie czynnych 1-feno- ksy-2-hydroksy-3-cykloalkiloaminopropanów i ich soli addycyjnych z kwasami.Nowym zwiazkom odpowiada wzór 1, w którym R oznacza grupe alkilowa, zawierajaca do 5 atomów wegla, Ri oznacza grupe nitrylowa (-C^N), grupe nitrowa lub trójfluorometylowa lub grupe alkilowa, alkenylowa, alkinylowa, alkoksylowa, alkenyloksylowa, alkinyloksylowa, alkoksyalkilowa, aminoalkilowa, alkilo- aminoalkilowa, dwualkiloaminoalkilowa, alkiloaminowa, dwualkiloaminowa, nitryloalkilowa, alkoksykarbony- lowa, alkiloaminokarbonylowa, alkilotio, acylowa, acyloksylowa lub acyloaminowa, zawierajaca do 5 atomów wegla, grupe arylowa, aralkilowa, aryloksylowa, aralkoksylowa lub aryloaminowa, zawierajaca do 10 atomów wegla lub chlorowiec, R2 oznacza wodór, chlorowiec lub grupe nitrylowa albo grupe alkilowa, alkoksylowa lub alkenylowa, zawierajaca do 5 atomów wegla, lub razem z R! oznacza grupe 3,4-metylenodwuoksylowa (bez dalszych podstawników), R3 oznacza wodór, chlorowiec, grupe alkilowa lub alkoksylowa, zawierajaca do 5 atomów wegla i n oznacza liczbe calkowita 2-7.Nowe zwiazki wytwarza sie przez reakcje epoksydu o wzorze 2a wzglednie ehlorowcohydryny o wzorze 2b, w których to wzorach Ri -R3 maja wyzej podane znaczenie, a Hal oznacza chlorowiec, z N,N'-dwucykloalki- lomocznikiem o wzorze 3. Reakcje prowadzi sie korzystnie w wysokowrzacym, nie mieszajacym sie z woda, rozpuszczalniku takim, jak np. tetralina, dekalina, benzonitryl itd., lub w stopie, w temperaturze 180-220 C, zwlaszcza 180-200°C.Jezeli w produktach wyjsciowych znajduja sie grupy wrazliwe na wyzsza temperature, wówczas reakcja przebiega z mala wydajnoscia.Potrzebny do przeprowadzenia sposobu wedlug wynalazku material wyjsciowy jest juz czesciowo znany, czesciowo mozna go otrzymac znanymi metodami. Epoksydy o wzorze 2a mozna latwo otrzymac przez reakcje odpowiedniego fenolu wzglednie fenolanu o wzorze 4, w którym Kt oznacza kation metalu alkalicznego, z epichlorohydryna. Epoksydy mozna równiez stosowac do wytworzenia drugiego materialu wyjsciowego, np. chlorowcohydryny o wzorze 2b, która wytwarza sie przez reakcje epoksydu z odpowiednim kwasem chlorowcowodorowym. Moczniki o wzorze 3 wytwarza sie np. przez reakcje fosgenu z odpowiednia amina.2 90039 Zwiazki otrzymywane sposobem wedlug wynalazku posiadaja asymetryczny atom wegla w grupie CHOH i moga wskutek tego wystepowac jako racematy i równiez w postaci optycznych antypodów. Teostatnie mozna otrzymac przez rozdzielanie racematu za pomoca zwykle uzywanych kwasów pomocniczych, takich jak kwas dwubenzoilo-D-winowy lub D-3-bromokamforo-8-sulfonowy i przez stosowanie optycznie czynnych zwiazków wyjsciowych.Otrzymywane sposobem wedlug wynalazku 1-fenoksy-3-cykloalkiloaminopropanple o wzorze 1, mozna przeprowadzic w ich fizjologicznie dopuszczalne sole addycyjne z kwasami. Odpowiednimi kwasami, sa np. kwas solny, kwas bromowodorowy, kwas siarkowy, kwas metanosulfonowy, kwas maleinowy, kwas octowy, kwas szczawiowy, kwas mlekowy, kwas winowy lub 8-chloroteofilina.Zwiazki o wzorze 1 wzglednie ich sole addycyjne z kwasami wykazuja w badaniach na swinkach morskich, jako zwierzetach doswiadczalnych, wartosciowe wlasciwosci terapeutyczne, w szczególnosci j3-adrenolityczne i nadaja sie wskutek tego do leczenia lub profilaktyki w schorzeniach naczyn wiencowych serca i do traktowania arytmii serca, w szczególnosci tachycardii, w medycynie. Równiez dzialanie obnizajace cisnienie krwi wywoly¬ wane przez te zwiazki jest pod wzgledem terapeutycznym interesujace.Szczególnie wartosciowymi przy tym okazaly sie zwiazki o wzorze 1, w którym R oznacza grupe metylowa, R2 i R3 oznaczaja zwlaszcza wodór, dalej grupe alkilowa i Ri oznacza zwlaszcza nienasycona grupe, taka jak grupa etynylowa, nitrylowa, allilowa lub alliloksylowa, w szczególnosci w polozeniu 2 lancucha propanolowego, i n = 4,5 lub 6. Równiez, gdy R oznacza grupe metylowa, Ri oznacza chlorowiec, a R2 oznacza wodór lub grupe metylowa i R3 oznacza wodór, a n = 4,5 lub 6, takie zwiazki wykazuja silne dzialanie )3-adrenolityczne. Szczególnie wartosciowymi pod wzgledem terapeutycznym sa w szczególnosci 1-(2 -etynylofei- . / noksy)-2-hydroksy-3-(1-metylocyklopentylo)- aminopropan, jak i 1-(2-nitrylofenoksy)-2-hydroksy-3-(1-metylo- ^ cyklopentylo)-aminopropan oraz 1-(2-nitrylofenoksy)-2-hydroksy-3-(1-metylocykloheksylo)-aminopropan, 1-(2% .. chloro-5-metylofenoksy)-2-hydroksy-3- (1-metylocyklopentylo) -aminopropan i 1-(2-bromofenoksy)-2-hydroksy- 3-(1-metylocykloheptylo)-aminopropan wzglednie ich fizjologicznie dopuszczalne sole addycyjne z kwasami. 1-(2-nitrylofenoksy)-2-hydroksy- -3-(1-metylocyklopentylo)-aminopropan jest szczególnie interesujacym wskutek wybitnego dzialania antagonistycznego wobec izoproterenolu, przy prawie calkowitym braku dzialania wlas¬ nego powodujacego rzadkoskurcz. Szczególnie dobre dzialanie maja zwiazki, w których grupa fenylowa podstawiona jest w polozeniu 2 grupa nitrylowa i jednoczesnie nizsza grupa alkilowa, zwlaszcza metylowa w polozeniu 5, np. 1-(2-nitrylo-5-metylofenoksy)-2-hydroksy-3-(1-metylocyklopentyloamino)-propan, 1-(2-nitry~ lo-5-metylofenoksy)-2-hydroksy-3-(1-metylocy kloheksyloamino)-propan i 1 (2-nitrylo-5-metylofenoksy)^-hy¬ droksyli-metylocykloheptyloamino)-propan wzglednie ich fizjologicznie dopuszczalne sole addycyjne z kwa¬ sami.Dawka jednostkowa zwiazków wytwarzanych sposobem wedlug wynalazku wynosi 1—300 mg, zwlaszcza —100 mg (doustnie) wzglednie 1—20 mg (pozajelitowo).Galenowa obróbke zwiazków, otrzymywanych sposobem wedlug wynalazku, do zwykle stosowanych postaci uzytkowych, takich jak roztwory, emulsje, tabletki, drazetki lub preparaty o przedluzonym dzialaniu, prowadzi sie w znany sposób, stosujac zwykle uzywane galenowe srodki pomocnicze, nosniki, srodki rozkrusza- jace, wiazace, powlokowe lub nadajace poslizg, substancje smakowe, slodzace, srodki do wywolywania przedluzonego dzialania lub ulatwiajace rozpuszczanie. Zwiazki, otrzymywane sposobem wedlug wynalazku, mozna równiez laczyc z innymi substancjami farmakodynamicznie aktywnymi, jak np. rozszerzajacymi naczynia wiencowe, sympatykomimetycznymi, glikozydami nasercowymi lub o dzialaniu uspokajajacym.Nastepujacy przyklad wyjasnia blizej wynalazek nie ograniczajac jego zakresu: Przyklad. Chlorowodorek 1-(2-bromofenoksy)-2-hydroksy-3-(1 -mety locykloheksyloam ino) -propanu. 1,16 g (0,00375 mola) 1-(2-bromofenoksy)-2-hydroksy-4-bromopropanu w 10 ml tetraliny ogrzewa sie z 1,8 g (0,0075 mola) N,N'-bis-(1-metylocykloheksylo)-mocznika do temperatury 180—200°C przez 2 godziny.Po oziebieniu dodaje sie 50 ml eteru i wytrzasa z In HCI ekstrahujac nim zasadowa substancje. Faze wodna wytrzasa sie z eterem i alkalizuje za pomoca NaOH. Wytracony zasadowy produkt rozpuszcza sie w eterze, po oziebieniu przemywa woda i suszy nad MgS04. Po oddestylowaniu eteru pozostalosc rozpuszcza sie w malej ilosci etanolu i zadaje eterowym roztworem HCI. Wytracone krysztaly oddziela sie i suszy. Wydajnosc: 300 mg, temperatura topnienia: 154—156°C.Sposobem opisanym w przykladzie wytwarza sie nastepujace dalsze zwiazki o wzorze 1:90039 3 Temperatura topnienia Rt R2 R3 R n w°C (chlorowodorek) 2-CN 2-CN 2-Br 2-CI 2-CH,OCH 2-CHaCH=CH2 2-OCH 2-Br 2-Cl 2-a 2-CN 2-CH3C^CH 2-CH2CH=CH2 2-teCH 2-CH3 2-CN 2-a 2-CN 2-CH2OCH 2-CH2CH=CH3 2-CH2CH=CH2 2-CH2CH=CH2 2-CN 2-CN 2-CN 2-CN H H II -CH3 H H H H - CH3 -CH3 H H H H 4- H ' 5- H H H H H 4- - - CN CH3 a CH3 GH3 -CH3 H H H H H H H H H H H H H H H H H H H H H H H H H H CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH, CH3 C,H5 C2H5 CH3 CH3 CH3 CH3 i-C3H7 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 4 4 4 4 6 4 4 6 6 6 6 4 6 4 163-165 132-134 ' 156-157 170-172 137-138 141-143 (szczawian) 171-173 167-168 174-177 179-180 157-158 167-168 110-111 184-185 206-207 200-201 191-194 160-161 110-111 124-126 97- 99 100-101 (szczawian) 194-196 173-176 192-194 143-146 QO PL PL PL PL
Claims (4)
1. Z astrzezenie patento we Sposób wytwarzania nowych 1. -fenoksy-
2. -hydroksy-
3. -cykloalkiloaminopropanów o wzorze 1, w którym R oznacza grupe alkilowa, zawierajaca do 5 atomów wegla, Ri oznacza grupe nitrylowa (—C^N), nitrowa lub trójfluorometylowa, lub grupe alkilowa, alkenylowa, alkinylowa, alkoksylowa, alkenyloksyIowa, alkinyloksyIo¬ wa, alkoksyalkilowa, aminoalkilowa, alkiloaminoalkilowa, dwualkiloaminoalkilowa, alkiloaminowa, dwualkilo- aminowa, nitryloalkilowa, alkoksykarbonylowa, alkiloaminokarbonylowa, alkilotio, acylowa, acyloksylowa lub acyloaminowa, zawierajaca do 5 atomów wegla, grupe arylowa, aralkilowa, aryloksylowa, aralkoksylowa lub aryloaminowa, zawierajaca do 10 atomów wegla lub chlorowiec, R2 oznacza wodór, chlorowiec, grupe nitrylowa lub grupe alkilowa, alkoksylowa lub alkenylowa, zawierajaca do 5 atomów wegla, R3 oznacza wodór, atom chlorowca, grupe alkilowa lub alkoksylowa, zawierajaca do 5 atomów wegla lub Rx i R2 razem oznaczaja grupe 3,
4. -metylenodwuoksylowa i w tym przypadku R3 oznacza atom wodoru, n oznacza liczbe calkowita 2—7, w postaci racematu lub izomerów optycznie czynnych oraz ich fizjologicznie dopuszczalnych soli addycyjnych z kwasami, znamienny tym, ze epoksyd o wzorze 2a lub chlorowcohydryne o wzorze 2b, w których to wzorach Rx— R3 maja wyzej podane znaczenie, a Hal oznacza chlorowiec, poddaje sie reakcji z N,N'-dwualkilo- mocznikiem o wzorze 3, w którym R i n maja wyzej podane znaczenie i otrzymany zwiazek o wzorze 1, o ile wystepuje w postaci racematu, ewentualnie przeprowadza za pomoca odpowiedniego kwasu pomocniczego w jego diastereomeryczne sole, które rozdziela sie przez frakcjonowana krystalizacje na optyczne antypody i zwiazki o wzorze 1 ewentualnie przeprowadza w sole addycyjne z kwasami. CZYTELNIA Urzed* Rri—|»»ug#90 039 S^S „ , y -OCH-CHOH-CH-NH-C (CH )n *2 o R WZdR 1 R. ^j^-0CH2-CH-CH2 R, o WZdR 2a K2 R OH WZdR 2b v_^| | ^ n R O R WZdR 3 J, /N Ra' H^ R3 WZdR 4 OKt Prac. Poligraf. UP PRL naklad 120+18 Cena 10 zl G2.YTF LNIA Urzedi Pa*fB PL PL PL PL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1937477A DE1937477C3 (de) | 1969-07-23 | 1969-07-23 | I -Phenoxy-2-hydroxy-3-(l -methylcycloalkylamino)-propane, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL90039B1 true PL90039B1 (pl) | 1976-12-31 |
Family
ID=5740681
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173767A PL90030B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173770A PL90027B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173765A PL90039B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173772A PL90025B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173768A PL90029B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173771A PL90026B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970142196A PL79772B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173769A PL90028B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173766A PL90038B1 (pl) | 1969-07-23 | 1970-07-21 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173767A PL90030B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173770A PL90027B1 (pl) | 1969-07-23 | 1970-07-21 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173772A PL90025B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173768A PL90029B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173771A PL90026B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970142196A PL79772B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173769A PL90028B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173766A PL90038B1 (pl) | 1969-07-23 | 1970-07-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3755413A (pl) |
| JP (5) | JPS5133106B1 (pl) |
| AT (9) | AT304475B (pl) |
| BE (1) | BE753774A (pl) |
| BG (9) | BG17508A3 (pl) |
| CH (10) | CH550139A (pl) |
| CS (9) | CS170528B2 (pl) |
| DE (1) | DE1937477C3 (pl) |
| DK (1) | DK140281B (pl) |
| ES (8) | ES382014A1 (pl) |
| FR (1) | FR2059551B1 (pl) |
| GB (1) | GB1314896A (pl) |
| NL (1) | NL169874C (pl) |
| PL (9) | PL90030B1 (pl) |
| RO (9) | RO60112A (pl) |
| SE (1) | SE370391B (pl) |
| YU (5) | YU34395B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3937706A (en) * | 1969-07-23 | 1976-02-10 | Boehringer Ingelheim Gmbh | 1-(2'ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propanes and salts thereof |
| US4021576A (en) * | 1969-07-23 | 1977-05-03 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing a 1-(2'-ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propane and method of use |
| US4038313A (en) * | 1970-01-08 | 1977-07-26 | Ciba-Geigy Corporation | Cycloalkylureido phenoxy propanolamines |
| US4120978A (en) * | 1970-01-08 | 1978-10-17 | Ciba-Geigy Corporation | Pharmaceutical composition for inhibiting and blocking cardioselective beta-receptors |
| SE354851B (pl) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
| US4145442A (en) * | 1972-04-04 | 1979-03-20 | Aktiebolaget Hassle | Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases |
| US4038414A (en) * | 1972-06-08 | 1977-07-26 | Ciba-Geigy Corporation | Amines and processes for their manufacture |
| US4035420A (en) * | 1972-07-06 | 1977-07-12 | Aktiebolaget Hassle | Substituted ureido alkylene phenoxy propanolamines |
| DE2309887C2 (de) * | 1973-02-28 | 1983-11-10 | C.H. Boehringer Sohn, 6507 Ingelheim | 1-Aryloxy-2-hydroxy-3-alkinylaminopropan-Derivate und deren physiologisch verträgliche Säureadditionssalze, pharmazeutische Präparate und Herstellungsverfahren für die Verbindungen |
| US4220659A (en) * | 1974-02-22 | 1980-09-02 | Boehringer Ingelheim Gmbh | 1-Phenoxy-2-hydroxy-3-alkynylamino-propanes and salts thereof |
| DK405775A (da) * | 1974-09-12 | 1976-03-13 | American Cyanamid Co | Fremgangsmade til fremstilling af alkanolaminer |
| US4165384A (en) * | 1974-11-01 | 1979-08-21 | Aktiebolaget Hassle | Amide substituted phenoxy propanol amines |
| US4387103A (en) * | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
| US4471127A (en) * | 1981-09-08 | 1984-09-11 | Ciba-Geigy Corporation | 1-5-Bis-(1,4-benzodioxin-2-yl)-3-azapentane-1,5-diols |
| US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
| JPS6364630U (pl) * | 1986-10-17 | 1988-04-28 |
-
1969
- 1969-07-23 DE DE1937477A patent/DE1937477C3/de not_active Expired
-
1970
- 1970-03-22 BG BG017138A patent/BG17508A3/xx unknown
- 1970-03-23 BG BG017134A patent/BG17750A3/xx unknown
- 1970-07-16 CH CH224973A patent/CH550139A/xx not_active IP Right Cessation
- 1970-07-16 CH CH1087370A patent/CH537360A/de not_active IP Right Cessation
- 1970-07-16 CH CH224273A patent/CH536809A/de not_active IP Right Cessation
- 1970-07-16 CH CH1106675A patent/CH575376A5/xx not_active IP Right Cessation
- 1970-07-16 CH CH224673A patent/CH536811A/de not_active IP Right Cessation
- 1970-07-16 CH CH224473A patent/CH550140A/xx not_active IP Right Cessation
- 1970-07-16 CH CH224873A patent/CH536813A/de not_active IP Right Cessation
- 1970-07-16 CH CH224573A patent/CH536810A/de not_active IP Right Cessation
- 1970-07-16 CH CH224373A patent/CH570363A5/xx not_active IP Right Cessation
- 1970-07-16 CH CH224773A patent/CH536812A/de not_active IP Right Cessation
- 1970-07-20 RO RO69799A patent/RO60112A/ro unknown
- 1970-07-20 RO RO69806A patent/RO59211A/ro unknown
- 1970-07-20 RO RO63988A patent/RO56318A/ro unknown
- 1970-07-20 RO RO69803A patent/RO59159A/ro unknown
- 1970-07-20 RO RO69804A patent/RO59209A/ro unknown
- 1970-07-20 RO RO69798A patent/RO60111A/ro unknown
- 1970-07-20 RO RO69805A patent/RO59210A/ro unknown
- 1970-07-20 RO RO69802A patent/RO59089A/ro unknown
- 1970-07-20 RO RO69801A patent/RO59112A/ro unknown
- 1970-07-21 PL PL1970173767A patent/PL90030B1/pl unknown
- 1970-07-21 CS CS4505A patent/CS170528B2/cs unknown
- 1970-07-21 PL PL1970173770A patent/PL90027B1/pl unknown
- 1970-07-21 CS CS4507A patent/CS170530B2/cs unknown
- 1970-07-21 GB GB3535970A patent/GB1314896A/en not_active Expired
- 1970-07-21 PL PL1970173765A patent/PL90039B1/pl unknown
- 1970-07-21 CS CS4506A patent/CS170529B2/cs unknown
- 1970-07-21 PL PL1970173772A patent/PL90025B1/pl unknown
- 1970-07-21 ES ES382014A patent/ES382014A1/es not_active Expired
- 1970-07-21 PL PL1970173768A patent/PL90029B1/pl unknown
- 1970-07-21 CS CS5136A patent/CS170524B2/cs unknown
- 1970-07-21 CS CS4504A patent/CS170527B2/cs unknown
- 1970-07-21 PL PL1970173771A patent/PL90026B1/pl unknown
- 1970-07-21 CS CS4508A patent/CS170531B2/cs unknown
- 1970-07-21 PL PL1970142196A patent/PL79772B1/pl unknown
- 1970-07-21 CS CS4509A patent/CS170532B2/cs unknown
- 1970-07-21 CS CS4502A patent/CS170525B2/cs unknown
- 1970-07-21 PL PL1970173769A patent/PL90028B1/pl unknown
- 1970-07-21 CS CS4503A patent/CS170526B2/cs unknown
- 1970-07-21 PL PL1970173766A patent/PL90038B1/pl unknown
- 1970-07-22 BG BG017136A patent/BG17507A3/xx unknown
- 1970-07-22 BG BG018645A patent/BG19132A3/xx unknown
- 1970-07-22 BE BE753774D patent/BE753774A/xx not_active IP Right Cessation
- 1970-07-22 JP JP45063634A patent/JPS5133106B1/ja active Pending
- 1970-07-22 BG BG015254A patent/BG17749A3/xx unknown
- 1970-07-22 YU YU1860/70A patent/YU34395B/xx unknown
- 1970-07-22 BG BG017137A patent/BG18852A3/xx unknown
- 1970-07-22 US US00057353A patent/US3755413A/en not_active Expired - Lifetime
- 1970-07-22 DK DK380170AA patent/DK140281B/da unknown
- 1970-07-22 BG BG017135A patent/BG17751A3/xx unknown
- 1970-07-23 FR FR7027291A patent/FR2059551B1/fr not_active Expired
- 1970-07-23 AT AT118272A patent/AT304475B/de active
- 1970-07-23 AT AT674870A patent/AT303706B/de not_active IP Right Cessation
- 1970-07-23 SE SE7010200A patent/SE370391B/xx unknown
- 1970-07-23 AT AT118372A patent/AT304476B/de not_active IP Right Cessation
- 1970-07-23 AT AT118172A patent/AT304474B/de active
- 1970-07-23 AT AT117972A patent/AT306702B/de not_active IP Right Cessation
- 1970-07-23 AT AT118672A patent/AT306704B/de not_active IP Right Cessation
- 1970-07-23 AT AT118572A patent/AT304478B/de active
- 1970-07-23 AT AT118472A patent/AT304477B/de not_active IP Right Cessation
- 1970-07-23 AT AT118072A patent/AT306703B/de not_active IP Right Cessation
- 1970-07-23 NL NLAANVRAGE7010928,A patent/NL169874C/xx not_active IP Right Cessation
- 1970-07-24 BG BG017133A patent/BG17506A3/xx unknown
- 1970-07-24 BG BG017132A patent/BG17505A3/xx unknown
-
1971
- 1971-09-09 ES ES394916A patent/ES394916A1/es not_active Expired
- 1971-09-09 ES ES394914A patent/ES394914A1/es not_active Expired
- 1971-09-09 ES ES394918A patent/ES394918A1/es not_active Expired
- 1971-09-09 ES ES394915A patent/ES394915A1/es not_active Expired
- 1971-09-09 ES ES394913A patent/ES394913A1/es not_active Expired
- 1971-09-09 ES ES394917A patent/ES394917A1/es not_active Expired
- 1971-09-09 ES ES394919A patent/ES394919A1/es not_active Expired
-
1973
- 1973-06-06 JP JP48063730A patent/JPS5210863B1/ja active Pending
- 1973-06-06 JP JP48063729A patent/JPS5210862B1/ja active Pending
- 1973-06-06 JP JP48063727A patent/JPS5238556B1/ja active Pending
- 1973-06-06 JP JP48063728A patent/JPS5210861B1/ja active Pending
-
1975
- 1975-10-07 YU YU2545/75A patent/YU34662B/xx unknown
- 1975-10-07 YU YU2544/75A patent/YU34396B/xx unknown
- 1975-10-07 YU YU2546/75A patent/YU34663B/xx unknown
- 1975-10-07 YU YU2551/75A patent/YU34113B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL90039B1 (pl) | ||
| JPH0579057B2 (pl) | ||
| PL113879B1 (en) | Process for preparing novel racemic or optically active1-aryloxy-2-hydroxy-3-alkylenaminopropanes | |
| US3974156A (en) | 2-(Substituted anilino) methylmorpholine compounds | |
| FR2479825A1 (fr) | Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments | |
| US3532685A (en) | N,n' - alkylene-n,n'-bis((alkoxy benzoyloxy)alkyl)alkylene diimines | |
| US4631281A (en) | Substituted phenylpiperazinyl-propanols, a process for their preparation and their use, and formulations containing these compounds | |
| PL96224B1 (pl) | Sposob wytwarzania nowych fenyloalkiloamin | |
| NO155880B (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktivt 2-(2'hydroksy-3'-(1,1-dimetylpropylamino)-propoksy)-beta-fenylpropionfenon. | |
| JP2004331669A (ja) | 欝病、不安神経症およびパ−キンソン病を治療するための1−アリールシクロアルキルスルフィド、スルホキシドおよびスルホン | |
| IE43258B1 (en) | 1-phenoxypenyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| JPS6326099B2 (pl) | ||
| FR2460294A1 (fr) | Nouveaux oxime-ethers, leur procede de preparation et compositions pharmaceutiques les contenant | |
| CS216525B2 (en) | Method of making the phenylpiperazine derivatives | |
| CS214841B2 (en) | Method of making the tetrahydrochinolines | |
| PL82037B1 (pl) | ||
| US5055490A (en) | Stereoisomers of benzonitrile derivatives, useful as cardiac arrhythmiac agents | |
| US3957845A (en) | Trifluoromethyl-substituted phenyl acetonitriles | |
| JPS63174949A (ja) | 新規カルボン酸誘導体、その製法、およびこれを含有する物質代謝疾患療用薬剤 | |
| CA1205472A (fr) | Benzo- et thieno-triazine-1,2,3 ones-4, procedes de preparation et medicaments les contenant | |
| US4147871A (en) | Cyclohexanetetrol derivatives | |
| US12297178B2 (en) | Triazole derivative and use thereof | |
| CS249145B2 (en) | Method of new beta-cycloalkyl-beta-phenylethylamines' production | |
| JPS5839832B2 (ja) | 新規ピラジン化合物の製法 | |
| US20020019440A1 (en) | Aryloxypropanolamine derivatives, method of preparation and applications thereof |